4SC AG
4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need.
4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat.
4SC had 46 employees as of 31 December 2021 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C4).
Fraunhoferstraße 22
Deutschland-82152 Martinsried
Telefon: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
http://www.4sc.com
public@
4sc.com